Related references
Note: Only part of the references are listed.Key metrics to expanding the pipeline of successful antibody-drug conjugates
Ian Nessler et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2021)
Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
Eshita Khera et al.
NEOPLASIA (2021)
Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect
K. C. Nicolaou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy
Jose F. Ponte et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
Sajad Yaghoubi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
Ian Nessler et al.
CANCER RESEARCH (2020)
Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
Mieke R. Van Bockstal et al.
MOLECULAR ONCOLOGY (2020)
Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect
Aman P. Singh et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Steven Coats et al.
CLINICAL CANCER RESEARCH (2019)
A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects
Jackson K. Burton et al.
AAPS JOURNAL (2019)
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
Bo Yu et al.
BIOMARKER RESEARCH (2019)
The Spatial and Genomic Hierarchy of Tumor Ecosystems Revealed by Single-Cell Technologies
Eric A. Smith et al.
TRENDS IN CANCER (2019)
Dual-Isotope Cryoimaging Quantitative Autoradiography: Investigating Antibody-Drug Conjugate Distribution and Payload Delivery Through Imaging
Ohad Ilovich et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis
Samuele Cazzamalli et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine
John A. Hartley et al.
SCIENTIFIC REPORTS (2018)
A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates
Jorge M. M. Verkade et al.
ANTIBODIES (2018)
Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival
Cornelius Cilliers et al.
CANCER RESEARCH (2018)
Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy
Eshita Khera et al.
MOLECULAR SYSTEMS DESIGN & ENGINEERING (2018)
From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
Julia Mantaj et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy
Cornelius Cilliers et al.
AAPS JOURNAL (2016)
Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology
Yusuke Ogitani et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Fu Li et al.
CANCER RESEARCH (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Antibody Drug Conjugates Differentiate Uptake and DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs of Xenograft Mice
Yong Ma et al.
DRUG METABOLISM AND DISPOSITION (2016)
Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates
Remon van Geel et al.
BIOCONJUGATE CHEMISTRY (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Structure-Guided Functional Characterization of Enediyne Self-Sacrifice Resistance Proteins, CalU16 and CalU19
Sherif I. Elshahawi et al.
ACS CHEMICAL BIOLOGY (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
Multichannel Imaging to Quantify Four Classes of Pharmacokinetic Distribution in Tumors
Sumit Bhatnagar et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
Dowdy Jackson et al.
PLOS ONE (2014)
Milatuzumab-SN-38 Conjugates for the Treatment of CD74 Cancers
Serengulam V. Govindan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
D. M. Collins et al.
ANNALS OF ONCOLOGY (2012)
Dose dependence of intratumoral perivascular distribution of monoclonal antibodies
John J. Rhoden et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Hans K. Erickson et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Apoptotic Phosphorylation of Histone H3 on Ser-10 by Protein Kinase Cδ
Choon-Ho Park et al.
PLOS ONE (2012)
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates
Hans K. Erickson et al.
BIOCONJUGATE CHEMISTRY (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters
Frederik B. Pruijn et al.
AUSTRALIAN JOURNAL OF CHEMISTRY (2008)
Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids
Greg M. Thurber et al.
CANCER RESEARCH (2008)
Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts
Jennifer H. E. Baker et al.
CLINICAL CANCER RESEARCH (2008)
Resistance to enediyne antitumor antibiotics by calC self-sacrifice
JB Biggins et al.
SCIENCE (2003)
Histone H3 phosphorylation and cell division
F Hans et al.
ONCOGENE (2001)
Share Paper
